Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 14/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1957828 | 0.81 | EPHX1 (0.43) | EPHX1ACHE | |
| SCHEMBL6343555 | 0.80 | EPHX1 (0.43) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL6343556 | 0.80 | EPHX1 (0.43) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL1070748 | 0.79 | NPC1 (0.42) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16230861 | 0.79 | EPHX1 (0.50) | RAB9AEPHX1NPC1SMN1; SMN2ACHE | |
| SCHEMBL1126448 | 0.78 | ALDH1A1 (0.50) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL4451188 | 0.78 | RAB9A (0.61) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL590532 | 0.78 | EPHX1 (0.59) | RAB9AMAPTNPSR1EPHX1ACHE | |
| SCHEMBL8575690 | 0.78 | ALDH1A1 (0.43) | RAB9AMAPTEPHX1NPC1SMN1; SMN2 | |
| SCHEMBL8575692 | 0.78 | ALDH1A1 (0.43) | RAB9AMAPTEPHX1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409459-B1 | ECL LABELS HAVING IMPROVED NON-SPECIFIC BINDING PROPERTIES, METHODS OF USING AND KITS CONTAINING THE SAME | IGEN INT INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-6808939-B2 | LIGAND FOR USE AS TOOL IN DIAGNOSTIC ANALYSIS | IGEN INTERNATIONAL, INC. | 2004-10-26 | — | — | US | disclosed |
| US-20030027357-A1 | ECL labels having improved non-specific binding properties, methods of using and kits containing the same | BIOVERIS CORPORATION | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027357-A1 | ECL labels having improved non-specific binding properties, methods of using and kits containing the same | HLCS, NONO, EBPL | RAB9A 1998/4885MAPT 4574/4885NPSR1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.